FDA Approves Dual-Targeted Therapy for Head and Neck Cancer

Who is covering this

1. Medscape Center Factuality: Mostly factual US 6 hours ago
   FDA Grants Rybrevant Faspro Accelerated Approval for HNSCC

   An overall response rate of 42% secures the first approval in a decade for recurrent or metastatic disease after platinum-based chemotherapy.

2. Medpagetoday Center Factuality: Mostly factual US 7 hours ago
   FDA Approves Dual-Targeted Therapy for Head and Neck Cancer

   (MedPage Today) -- The FDA granted accelerated approval to subcutaneous amivantamab and hyaluronidase (Rybrevant Faspro) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma. The approved indication is...